IDEAYA Biosciences Inc (NASDAQ: IDYA), a California-based precision medicine oncology company, announced on Sunday that it has entered an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload ADC program, with Jiangsu Hengrui Pharmaceuticals Co, Ltd (Hengrui Pharma, SHA: 600276), a global pharmaceutical company headquartered in China.

Under the terms of the contract, IDEAYA is to develop and commercialise SHR-4849 globally outside of Greater China.

SHR-4849 is claimed to have indicated promising antitumor activity in preclinical studies, which includes tumour regression as a monotherapy in multiple models. Presently, the product is being assessed in a phase one clinical trial for advanced solid tumours in China (NCT06443489).

Jiangsu is aiming to file a US IND for SHR-4849 in the first half of 2025.